

2018-19 EMERGING THERAPIES FOR PBC, NASH ESLD AND HCC SEMINAR SERIES

San Diego, CA – December 1, 2018

Conference Location **San Diego Marriott La Jolla** **Phone: (858)-587-1414**
 4240 La Jolla Village Drive <https://www.marriott.com/hotels/maps/travel/sanj-san-diego-marriott-la-jolla>
 La Jolla, California 92037

Parking at the Conference A reduced parking rate of \$12 for the day has been arranged for all seminar participants.
 Please bring your ticket to the Seminar Registration Desk to pick up the discount voucher. Street parking is also available.

Driving Directions
From Interstate 5 - Northbound - Exit La Jolla Village Drive and turn right toward East. Turn left on Regents Road and immediately turn right to Regent Park Row. Hotel driveway is on the right side
From Interstate 5 - Southbound - Exit La Jolla Village Drive and turn left toward the East. Turn left on Regents Road and immediately turn right to Regent Park Row. Hotel driveway is on the right side

Seminar Agenda and Syllabus Information
 Registration and breakfast begin at **7:30 a.m.** in the **Grand Ballroom – Section E.** Please check signage for any last minute room changes.
The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.

<i>7:30 am</i>	<i>Registration, Continental Breakfast & View Exhibits</i>
8:00 am	Opening Comments and Pre-Test
8:20 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant <ul style="list-style-type: none"> • Staging, workup, and diagnosis of cirrhosis • Medical care of the patient with end stage liver disease Liver Transplantation <ul style="list-style-type: none"> • Listing criteria, MELD scores, Exceptions and the transplant process Case Study 1 – Cirrhosis and Encephalopathy
9:25 am	Hepatocellular Carcinoma (HCC) <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Surgery
<i>10:00 am</i>	<i>Break & View Exhibits</i>
10:15 am	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> • Current FDA-Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma
11:00 am	Primary Sclerosing Cholangitis (PSC) <ul style="list-style-type: none"> • Epidemiology • Ursodiol and Antibiotic Treatments • Predicting outcomes and Improving Survival

11:25 am	New Treatments for PBC <ul style="list-style-type: none"> • Causes and Markers of PBC • Treatment management • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
12:00 pm	Hosted Luncheon and Educational Session “LAL-D: Lysosomal Acid Lipase Deficiency- Implementing Rule-out testing in patients with elevated ALT and LDL-C
12:45 pm	Coffee and Dessert & View Exhibits
1:00 pm	The Best Use of Non-Invasive Imaging for Fibrosis Assessment <ul style="list-style-type: none"> • Technologies, Procedures and Outcomes
1:30 pm	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> • Epidemiology, Demographics and Diagnosis • Treatment options for thrombocytopenia; including alternatives to platelet transfusion. • Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult Fatty Liver Disease
2:15 pm	Break & View Exhibits
2:30 pm	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> • Current therapies for NASH • Life style changes as a therapy • Drugs in clinical development for NASH Case Study 3 - NASH Diagnosis and Treatment
3:30 pm	Post-test and Wrap-Up <ul style="list-style-type: none"> • Session adjourns at 3:45pm

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.


Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Information

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.2 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1085. The Kentucky Board of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)TM organizations accredited by ACCME.

**Your Seminar
Faculty**



PAUL J. POCKROS, MD

Paul Pockros joined the gastroenterology/hepatology division at Scripps Clinic, La Jolla, California in 1985, where he is currently the Director of the Liver Disease Center and Director of Clinical Research of the Scripps Translational Science Institute. He is also the President/Founder of SC Liver Research Consortium.

Dr Pockros has over 300 published manuscripts and abstracts in peer-reviewed journals coverings areas such as chronic viral hepatitis, liver transplantation, complications of cirrhosis, alcoholic, metabolic and fatty liver diseases, and diagnostic tests for liver disorders [H score=54]. He is invited to lecture regularly at universities, medical societies, and regional conferences and he routinely presents his research at national and international congresses.



ROBERT G. GISH, MD

Dr. Gish began his medical training in 1974 when he was enrolled in the Pharmacy School at the University of Kansas. He transferred to the University of Kansas Medical School in 1977 and finished his MD degree in 1980. He went on to complete a 3-year Internal Medicine residency at the University of California, San Diego and a 4-year Gastroenterology and Hepatology fellowship including transplant medicine.

Dr. Gish had and continues to have an active research program in viral hepatitis, liver transplant, bioartificial livers, and public policy especially related to liver cancer, liver transplantation, and viral hepatitis. Although his primary research focus is clinical research, he frequently collaborates with basic scientists in his research activities. He has published more than 600 original articles, review articles, abstracts and book chapters



LISA RICHARDS, FNP-BC, MSN

Lisa Richards is a board certified Family Nurse Practitioner with the University of California Medical Center, San Diego. She received her bachelor and master's of science degree in nursing, magna cum laude, from the University of San Diego.

She practices in hepatology and has over 15 years of experience. She is a member of the American Association for the Study of Liver Disease and has served on many committees and is currently co-chair of the Hepatology Associate Special Interest Group. Additionally, she is chair of the local American Liver Foundation Associate Medical Advisory Committee. She is very active in the field of Hepatology and is an international and national speaker.